Abstract: Objective The aim of this study was to investigate the virological response of patients with genotype 1b infected chronic hepatitis C (CHC) to combination of ombitasvir and dasabuvir antiviral therapy. Methods A total of 106 patients with genotype 1b infected CHC were enrolled in our hospital between January 2020 and January 2022, 53 patients in the observation group were treated with ombitasvir and dasabuvir combination and other 53 patients in the control group were treated with dasabuvir alone. The antiviral regimen lasted for 12 weeks in the two groups. Serum HCV RNA load was detected by real-time fluorescence quantitative PCR, and the super rapid virological response (SRVR), rapid virological response (RVR), end of treatment virological response (ETVR) and sustained virological response (SVR) were recorded. Results The SRVR, RVR, ETVR and SVR in the observation group were 88.7%, 94.3%, 100.0% and 100.0%, all significantly higher than 67.9%, 75.4%, 83.0% and 90.5% (P<0.05) in the control; at the end of 12 week treatment, serum ALT and AST levels in the observation group were (30.8±4.6)U/L and (29.7±2.4)U/L, both significantly lower than in the control group; during the period of antiviral treatment, the incidence of untoward effects in the observation group was 18.7%, much higher than 9.4%(P＜0.05) in the control group. Conclusion The combination of ombitasvir and dasabuvir in the treatment of patients with genotype 1b infected CHC is efficacious, with high virological response and improved liver function tests and relatively good safety.

Key words: Hepatitis C, Genotype 1b, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, Virological response, Therapy